Status:
COMPLETED
Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose to Japanese healthy subjects.
Eligibility Criteria
Inclusion
- Weight between 45 to 100 kg and a body mass index (BMI) between 19 to 28 kg/m2
- Japanese males aged between 20 to 45 years old (young) and Japanese males or females aged between 65 to 80 years old (elderly)
Exclusion
- History of previous or ongoing somatic or psychiatric disease/condition
- Abnormalities in ECG that may interfere with interpretation of data.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00972049
Start Date
September 1 2009
End Date
December 1 2009
Last Update
March 4 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Fukuoka, Japan